



The Nifty ended 0.01% up at 15,576.20. It opened on a flat note and remained lackluster throughout the session towards finishing off on a flat note. Narrow range-bound movement led to a spinning-top candle, which implies indecision. Chart pattern suggests, 15,600-15,650 is likely to act as the thick resistance as of now while the short-term critical support is placed around 15,300 levels. Index majors not showing strength is still a major concern. Hence, staying cautious on rise is advised. Nifty probable trading range is likely to be 15,650-15,300.

On the Nifty hourly chart, stochastic oscillator recovered from the oversold zone led to intraday recovery and may push the benchmark index further higher towards challenging 15,650.

Nifty patterns on multiple time frames suggest; intraday recovery from around 15,450 suggests, the benchmark index may again challenge 15,650. Probable trading range is likely to be 15,650-15,300.

### Nifty Crucial Supports & Resistances-

**Supports- 15450, 15300 Resistances- 15600, 15650**

### Open Positional Calls-

T+3 Positional Buy-  
|Cash Segment| PFC @ 117-116,  
TGT- 124, Closing SL- 112

T+3 Positional Buy-  
|Cash Segment| NMDC on dips  
around @ 181-180, TGT- 190, SL-  
closing below 175

T+3 Positional Buy-  
|Cash Segment| M&M FIN on dips  
around @ 158-157, TGT- 167, SL-  
closing below 152

T+10 Positional Buy-  
|Cash Segment| EXIDE on dips  
around @ 192-190, TGT- 210, SL-  
closing below 180

T+5 Positional Buy-  
|Cash Segment| ASHOK LEYLAND @  
123-122, TGT- 132, Closing SL- 117

Key Contents	Page No.
Result Update	4
Domestic News	6

## Nifty Intraday Chart



## Market in Retrospect

The Nifty 50 index managed to close flat, powered by gains in Reliance Industries Ltd.

Nifty index ended 0.01% higher at 15,576. The broader markets represented by the NIFTY 500 Index ended 0.48% higher, ending at 13,274. Among the sectorial indices, NIFTY PSU Bank was the top gainer, gaining by 3.03%, followed by NIFTY Metal, gaining by 2.18% higher. NIFTY IT was the top loser, losing by 0.75%

UPL was the top gainer, gaining by 2.67%, followed by Tata Steel and SBI life which gained by 2.10% & 1.87% respectively. ITC was the top loser, losing by 2.90%, followed by Tech Mahindra and Axis Bank which fell by 1.31% & 1.09% respectively.

The Advance : Decline ratio stood at 1383:535

### Market Turnover (In Crore) 02-06-2021

Name	Last	Previous
NSE Cash	*NA	64176.40
NSE F&O	4328023.26	3932625.77
BSE Cash	5,452.16	4,533.80
BSE F&O	*NA	88.70

### FII Derivatives Flow (In Crore) 01-06-2021\*

Instrument	Purchase	Sale	Net
Index Future	4170.51	3756.69	413.82
Index Option	399942.23	401815.66	1873.43
Stock Future	12864.16	12649.33	214.83
Stock Option	13540.33	13854.87	314.54

### Institutional Flow (In Crore) 01-06-2021\*

Institution	Purchase	Sale	Net
FII	4507.92	4957.78	449.86
DII	4363.99	4133.50	230.49

\*Data not updated till 5:30pm

### NIFTY Top Gainers

Name	%1D	%5D	Day Vol	Avg 5 Day Vol
UPL	2.67	3.08	7228801	6185952
Tata Steel	2.10	3.87	12862591	18110380
SBI Life Insurance	1.87	1.30	2488600	1498484
Indusind Bank	1.78	2.96	4177378	3839914
Adani Ports & SE	1.67	7.02	27748928	10915180

### NIFTY Top Losers

Name	%1D	%5D	Day Vol	Avg 5 Day Vol
Kotak Bank	0.77	2.44	3098849	3206545
Asian Paints	0.93	1.29	2067842	1532941
Axis Bank	1.09	0.26	9973043	13041390
Tech Mahindra	1.31	0.91	5252186	2662213
ITC	2.90	0.76	96654991	40504510

### Bulk and Block Deals

<https://www.nseindia.com/products/content/equities/equities/bulk.htm>  
<http://www.bseindia.com/markets/equity/EQReports/BulknBlockDeals.aspx>

## Sensex Intraday Chart



## Market in Detailed (Updated after 4:00 PM)

### Indian Indices

Name	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
Sensex	51849.48	85.40	0.16	1.63	6.29	3.09	53.29
Nifty	15576.20	1.35	0.01	1.80	6.46	4.40	56.09
BSE M Cap	22140.66	379.96	1.75	2.64	9.00	7.56	79.97
BSE S Cap	23826.12	303.13	1.29	1.33	9.95	14.51	108.48
Nifty MC 100	26118.00	368.50	1.43	2.16	7.94	8.43	88.30
BSE Auto	23868.14	390.52	1.66	1.91	10.15	1.44	62.71
BSE Capgoods	22689.84	183.13	0.81	1.15	12.04	2.37	79.72
BSE FMCG	13075.01	59.83	0.46	0.73	4.53	6.71	19.24
BSE Metal	18840.63	270.12	1.45	3.29	5.72	33.68	165.76
BSE Oil&Gas	16703.53	114.73	0.69	3.81	11.39	4.56	38.39
BSE Healthcare	24720.49	183.28	0.75	0.06	5.06	15.69	56.29
BSE Power	2866.70	50.67	1.80	2.84	15.54	14.03	87.13
BSE Realty	2706.45	40.40	1.52	1.27	9.65	4.90	78.62
BSE ConsDur	33695.35	221.51	0.66	1.89	4.24	3.33	63.33
BSE Bank	40057.48	63.42	0.16	1.70	7.38	0.81	69.74
BSE IT	27374.45	147.26	0.54	0.37	4.06	7.64	89.09

### Bond Markets

Name	Yield	Net Chng	%1D	%5D	%1M	%3M	%1Y
US	1.60	0.00	0.21	1.72	1.42	15.19	133.92
UK	0.82	0.01	1.33	8.38	3.21	18.63	267.12
Brazil	3.73	0.01	0.35	2.28	6.63	4.79	25.42
Japan	0.08	0.00	0.00	12.16	14.43	35.16	591.67
Australia	1.68	0.01	0.53	0.72	3.61	2.27	85.76
India	6.01	0.02	0.30	0.03	0.40	3.64	4.27
Switzerland	0.15	0.00	2.74	23.47	25.00	45.65	62.87
Germany	0.19	0.01	7.87	6.80	4.95	45.46	53.74

### Currency

Name	Rate	Net Chng	%1D	%5D	%1M	%3M	%1Y
INR	73.08	0.18	0.25	0.42	1.17	0.39	3.11
USD Index	90.15	0.32	0.36	0.57	1.24	0.70	7.70
YUAN	6.39	0.00	0.08	0.08	1.39	1.32	11.20
GBP	1.41	0.00	0.10	0.12	1.62	1.30	12.63
EUR	1.22	0.00	0.31	0.14	0.92	0.69	9.00
YEN	109.84	0.36	0.33	0.63	0.70	2.87	1.06

### Freight

Name	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
Baltic Dry	2568.00	28.00	1.08	10.86	15.89	53.50	370.33
Baltic Dirty	598.00	6.00	0.99	2.61	1.32	10.88	8.42
SG Dubai HY	0.35	0.25	41.67	400.00	78.79	73.68	114.29

### Global Indices

Name	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
Dow Jones	34575.31	45.86	0.13	0.53	2.07	10.14	34.31
Nasdaq	13736.48	12.26	0.09	0.55	1.62	2.83	42.96
S&P 500	4202.04	2.07	0.05	0.12	0.50	8.57	36.39
FTSE100	7087.67	7.26	0.10	0.82	1.69	7.17	13.95
CAC40	6507.63	17.63	0.27	1.81	3.79	12.00	33.92
DAX	15595.91	26.42	0.17	0.93	3.03	11.07	29.72
Mexico IPC	50722.35	163.60	0.32	3.88	5.65	11.03	35.40
Brazil Bovespa	128267.1	2051.30	1.63	4.29	7.88	15.00	40.88
Russian RTS	1620.57	6.50	0.40	1.89	9.14	11.58	26.83
Japan Nikkei	28946.14	131.80	0.46	1.06	0.46	1.57	29.65
Hang Seng	29297.62	170.38	0.58	0.45	1.99	0.69	22.09
Taiwan Index	17165.04	2.66	0.02	3.13	2.29	7.64	54.25
Shanghai Comp	3597.14	27.58	0.76	0.11	4.36	2.52	23.13
KOSPI	3224.23	2.36	0.07	1.76	2.43	5.93	54.48
Malaysia KLCI	1597.94	12.04	0.76	1.28	0.23	1.79	5.99
Jakarta Comp	6031.58	84.12	1.41	4.65	0.60	4.84	26.88
Philippine SE	6841.69	214.26	3.23	7.89	7.39	1.13	13.55
Thai Exch	1617.55	1.04	0.06	3.12	2.17	7.60	17.71

### Indian Indices

Name	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
NYMEX Crude	68.38	0.66	0.97	3.50	7.55	14.44	85.76
BRENT Crude	71.06	0.81	1.15	3.39	7.21	16.34	65.49
Natural Gas	3.09	0.02	0.52	3.83	3.69	3.73	20.06

### LME

Name	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
Gold(\$/Ounce)	1896.11	4.39	0.23	0.03	7.17	9.07	9.74
Silver(\$/Ounce)	27.81	0.09	0.32	0.44	7.28	3.89	53.88
Aluminium	2449.95	8.56	0.35	4.01	1.76	15.84	62.36
Copper	10234.50	13.75	0.13	3.08	4.13	12.60	87.51
Zinc	3045.00	1.45	0.05	3.72	4.52	8.82	50.54
Lead	2219.75	23.50	1.07	4.44	3.87	7.87	33.86

### Agro Commodities

Name	Price	Net Chng	%1D	%5D	%1M	%3M	%1Y
Coffee	164.10	3.05	1.89	9.04	16.01	20.84	52.72
Cotton	84.76	0.05	0.06	2.01	0.35	1.95	43.18
Sugar	17.89	0.20	1.13	4.99	5.36	12.94	52.78
Wheat	699.50	6.00	0.87	6.55	4.80	6.79	31.12
Soybean	1560.50	12.00	0.77	3.22	1.71	11.56	79.11

### PVR Ltd

- Q4FY21 Consolidated Revenue from Operations was INR1,815 mln (-71.9% YoY). FY21 Consolidated Revenue from Operations was INR2,800 mln (-91.8% YoY).
- Q4FY21 Consolidated EBITDA was INR(567) mln (-132.9% YoY). FY21 Consolidated EBITDA was (3,349) mln (-131.1% YoY).
- Q4FY21 Consolidated EBITDA margin was -31.3% as against 26.8% in Q4FY20. FY21 Consolidated EBITDA margin was -119.6% as against 31.5% in FY20.
- Q4FY21 Consolidated PAT was INR(2,891) mln as against INR(745) mln in Q4FY20. FY21 Consolidated PAT was INR(7,478) mln as against INR273 mln in FY20.
- Q4FY21 Consolidated PAT margin was -159.3% as against -11.5% in Q4FY20. FY21 Consolidated PAT margin was -267.1% as against 0.8% in FY20.

### ITC Ltd

ITC reported a 22.64 per cent increase in consolidated revenue from operations for the quarter ended March, 2021, but clocked in a 2.7 per cent drop in profit after tax compared to the year-ago period, which included a lower tax cost. The comparable Q4 PAT was up 6.5 per cent, after adjusting for one-time benefit in the corresponding quarter of the previous year. Consolidated profit after tax stood at INR3,819.62 crore for the quarter ended March 31, 2021. It was at INR3,926.72 crore in the corresponding quarter of the previous year and INR3,587.09 crore in the previous quarter. Consolidated revenue from operations was up by 22.64 per cent to INR15,404.37 crore during the quarter from INR12,560.64 crore in the year ago period, which reflected disruptions due to lockdown towards the end of March. Segment wise, revenues from cigarettes stood at INR6508.43 crore, up 13.18 per cent from INR5,750.44 crore in the year ago period and 6.8 per cent from INR6,091.17 in the previous quarter. Non-cigarettes FMCG segment revenues stood at INR3,694.80 crore in the March quarter compared to INR3190.34 crore a year back, but down from INR3752.61 crore in the previous quarter. Hotels business was at INR302.35 crore, down from INR494.76 crore, but up from previous quarter's INR248.87 crore. Pre-tax loss narrowed from INR72.25 crore to INR40.26 crore in the March quarter. In the corresponding quarter of the previous year, it had posted a profit of INR38.27 crore.

### Gujarat Gas

Net profit of Gujarat Gas rose 40.09% to INR350.86 crore in the quarter ended March 2021 as against INR250.46 crore during the previous quarter ended March 2020. Sales rose 28.59% to INR3428.92 crore in the quarter ended March 2021 as against INR2666.63 crore during the previous quarter ended March 2020. For the full year, net profit rose 6.58% to INR1277.72 crore in the year ended March 2021 as against INR1198.82 crore during the previous year ended March 2020. Sales declined 4.33% to INR9854.25 crore in the year ended March 2021 as against INR10300.34 crore during the previous year ended March 2020.

### **Emami Paper Mills**

Emami Paper Mills reported net sales at INR411.38 crore in March 2021 up 9.82% from INR374.58 crore in March 2020. Quarterly Net Profit at INR47.28 crore in March 2021 up 252.27% from INR31.05 crore in March 2020. EBITDA stands at INR68.81 crore in March 2021 up 59.76% from INR43.07 crore in March 2020. Emami Paper EPS has increased to INR7.81 in March 2021 from INR5.13 in March 2020.

### **Motherson Sumi Systems**

Motherson Sumi Systems reported a 289 per cent year-on-year rise in its consolidated net profit to INR713.6 crore for the quarter ended March. The company's consolidated total revenue from operations jumped 17.6 per cent on-year to INR16,971.9 crore. The company's board also approved a final dividend worth INR1.5 per share for the financial year ended March, 2021. Revenues of the standalone entity rose 28 per cent on-year to INR1,269 crore during the quarter. The automotive interior and exterior business under Samvardhana Motherson Peguform saw its revenues rise 16 per cent on-year to INR8,746.7 crore.

### **Muthoot Finance**

Muthoot Finance declared a standalone net profit of INR995.66 crore during the quarter ended March 2021 (Q4), up 22.14 per cent from 815.15 crore a year ago. The gold financing company had a standalone net profit of 991.37 crore during the December quarter. For the financial year 2020-21 (FY21), Muthoot Finance reported a standalone profit of INR3,722.18 crore, up 23.32 per cent from 3,018.30 crore in 2019-20 (FY20). Apart from this, the company's standalone loan AUM increased 26 per cent year-on-year to INR52,622 crores in FY21.

### **Sun Pharma, Ferring Pharmaceuticals ink pact to introduce obstetric drug in India**

Sun Pharmaceutical Industries has entered into a licensing agreement with Ferring Pharmaceuticals to commercialise innovative obstetric drug Caritec in India. One of the company's wholly-owned subsidiaries has entered into a license agreement with Ferring Pharmaceuticals Pvt Ltd a subsidiary of Switzerland based Ferring Pharmaceuticals to commercialise a room temperature stable formulation of the obstetric drug Caritec in India. The drug is indicated for the prevention of excessive bleeding in women after vaginal or caesarean childbirth. As per the agreement, Sun Pharma is granted rights for co-marketing of the drug in India in the private market under the brand name Caritec. Ferring has developed the drug and received approval from the Drugs Controller General of India (DCGI) for introducing the medicine in India.

### **Pfizer, Moderna vaccines may soon be available in India**

Drugs Controller General of India (DCGI) has given a green signal to foreign vaccines to be approved in India without specific clinical trials in the country before usage. This could be a big step in making vaccination drive a bigger success. DCGI Chief VG Somani said that this will be applicable for vaccines that have already been approved for restricted use by the US FDA, EMA, UK MHRA, PMDA Japan or listed for Emergency Use by the World Health Organisation. In order to make vaccines available to the Indian population at the earliest and fulfil need for vaccine imports it has been decided that for approval of COVID-19 Vaccines in India for restricted use in emergency situation which are already approved for restricted use by US FDA, EMA, UK MHRA, PMDA Japan or which are listed in WHO Emergency Use listing.

### **Bharti Airtel sells its Tanzanian tower business for \$175 million**

Bharti Airtel on its Tanzanian tower operations for \$175 million (INR1,313 crore) in a bid to focus on asset-light and core subscriber-facing operations, with some of the funds being used to pare debt at the consolidated level. The latest offloading of tower assets in African countries and a stake sale in mobile money business to Mastercard and TPG has helped Airtel raise about \$725 million so far.

### **AGEL arm commissions 150-MW wind power project in Gujarat; 9 months ahead of schedule**

Adani Green Energy on its arm AWEKTL has commissioned a 150-megawatts (MW) wind power project in the Kutchh district of Gujarat, nine months ahead of schedule. This is its sixth project commissioned before schedule over the past 12 months. The project has a 25-year power purchase agreement (PPA) with Solar Energy Corporation of India (SECI) at INR2.82 per kilowatt-hour (kWh). This commissioning takes AGEL's total operational renewable capacity to 5,070 MW, a step closer to its vision of 25 GW capacity by 2025. With the successful commissioning of this plant, AGEL has an operational wind generation capacity of 647 MW. AGEL has a total renewable capacity of 24,294 MW, including assets under acquisition and projects where AGEL has emerged as the lowest (L1) bidder. With this 150 MW, AGEL has added a total operational renewable capacity of 2,525 MW, including 1,750 MW of operational assets under acquisition, during the COVID-19 outbreak.

### CORPORATE ACTION BONUS / RIGHTS / STOCK SPLIT / DIVIDEND / FCCB / M&A / WARRANTS ETC.

Company	Details
Raw Edge Industrial Solutions Ltd	Stock dividend of INR1.2 effective 03-06-2021
State Bank of India	Cash dividend of INR4 effective 03-06-2021
Cyient Ltd	Cash dividend of INR17 effective 03-06-2021
Gati Ltd	Corporate meeting effective 03-06-2021

### Domestic Events

- **Upcoming Result's:-** APL Apollo Tubes Ltd., Arvind Fashions Ltd., Cupid Ltd., General Insurance Corporation Of India., Gujarat State Petronet Ltd., Parle Industries Ltd., Roto Pumps Ltd.,
- India Markit Services and Composite PMI for May 2021.

### Global Events

- China Caixin Services and Composite PMI for May 2021.
- Japan Jibun Bank Services and Composite PMI for May 2021.
- Euro Area Markit Services and Composite PMI for May 2021.
- The U.S. Services and Composite PMI for May 2021.
- The U.S. Initial Jobless Claims for May 29, 2021.

Source of News : The content may have been taken from The Economic Times, Business Standard, Business Line, Mint and other leading financial newspapers and financial portals BSE,NSE, Bloomberg, Moneycontrol & others.

### **Analyst Certification:**

We /I, Deepankar Saha & Jaydeb Dey Research Analyst(s) of SMIFS Limited (in short “SMIFS / the Company”), authors and the names subscribed to this Research Report, hereby certify that all of the views expressed in this Research Report accurately reflect our views about the subject issuer(s) or securities and distributed as per SEBI (Research Analysts) Regulations 2014. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this Research Report. It is also confirmed that We/I, the above mentioned Research Analyst(s) of this Research Report have not received any compensation from the subject companies mentioned in the Research Report in the preceding twelve months and do not serve as an officer, director or employee of the subject companies mentioned in the Research Report.

### **Terms & Conditions and Other Disclosures:**

SMIFS Limited is engaged in the business of Stock Broking, Depository Services, Portfolio Management and Distribution of Financial Products. SMIFS Limited is registered as Research Analyst Entity with Securities & Exchange Board of India (SEBI) with Registration Number – INH300001474.

SMIFS and our associates might have investment banking and other business relationship with a significant percentage of companies covered by our Research Analysts. SMIFS generally prohibits its analysts, persons reporting to analysts and their relatives from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover.

The information and opinions in this Research Report have been prepared by SMIFS and are subject to change without any notice. The Research Report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of SMIFS Limited. While we would endeavor to update the information herein on a reasonable basis, SMIFS is under no obligation to update or keep the information current. Also, there may be regulatory, compliance or other reasons that may prevent SMIFS from doing so. Non-rated securities indicate that rating on a particular security has been suspended temporarily and such suspension is in compliance with applicable regulations and/or policies of SMIFS, in circumstances where SMIFS might be acting in an advisory capacity to this company, or in certain other circumstances.

This Research Report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This Research Report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Securities as defined in clause (h) of section 2 of the Securities Contract Act, 1956, includes Financial Instruments, Currency and Commodity Derivatives. Though disseminated to all the customers simultaneously, not all customers may receive this Research Report at the same time. SMIFS will not treat recipients as customers by virtue of their receiving this Research Report. Nothing in this Research Report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this Research Report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. The recipient should independently evaluate the investment risks. The value and return on investment may vary because of changes in interest rates, foreign exchange rates or any other reason. SMIFS accepts no liabilities whatsoever for any loss or damage of any kind arising out of the use of this Research Report. Past performance is not necessarily a guide to future performance. Investors are advised to see Risk Disclosure Document to understand the risks associated before investing in the securities markets. Actual results may differ materially from those set forth in projections. Forward-looking statements are not predictions and may be subject to change without notice. The information given in this report is as of date of this report and there can be no assurance that future results or events will be consistent with this information. The information provided in this report remains, unless otherwise stated, the copyright of SMIFS. All layout, design, original artwork, concepts and intellectual Properties remains the property and copyright of SMIFS and may not be used in any form or for any purpose whatsoever by any party without the express written permission of the SMIFS.



SMIFS shall not be liable for any delay or any other interruption which may occur in presenting the data due to any reason including network (Internet) reasons or snags in the system, breakdown of the system or any other equipment, server breakdown, maintenance shutdown, breakdown of communication services or inability of SMIFS to present the data. In no event shall SMIFS be liable for any damages, including without limitation direct or indirect, special, incidental, or consequential damages, losses or expenses arising in connection with the data presented by the SMIFS through this report.

Participants in foreign exchange transactions may incur risks arising from several factors, including the following: (a) Exchange Rates can be volatile and are subject to large fluctuations; (b) the value of currencies may be affected by numerous market factors, including world and notional economic, political and regulatory events, events in Equity & Debt Markets and changes in interest rates; and (c) Currencies may be subject to devaluation or government imposed Exchange Controls which could affect the value of the Currency. Investors in securities such as Currency Derivatives, whose values are affected by the currency of an underlying security, effectively assume currency risk.

Since associates of SMIFS are engaged in various financial service businesses, they might have financial interests or beneficial ownership in various companies including the subject company/companies mentioned in this Research Report.

SMIFS and its Associates, Officers, Directors, Employees, Research Analysts including their relatives worldwide may: (i) from time to time may have long or short positions in, and buy or sell the Securities, mentioned herein or (ii) be engaged in any other transaction involving such Securities and earn brokerage or other compensation or act as a market maker in the Financial Instruments of the Subject Company/ companies mentioned herein or act as an Advisor or Lender/Borrower to such Companies or have other potential/material Conflict of Interest with respect to any recommendation and related information and opinions at the time of the publication of the Research Report. Or at the time of Public Appearance. SMIFS does not have proprietary trades but may at a future date, may opt for the same with prior intimation to Clients/ Investors and extant Authorities where it may have proprietary long/ short position in the above Scrip(s) and therefore should be considered as interested. The views provided herein are general in nature and do not consider Risk Appetite or Investment Objective of any particular Investor; Clients/ Readers/ Subscribers of this Research Report are requested to take independent professional advice before investing. The information provided herein should not be construed as invitation or solicitation to do business with SMIFS.

SMIFS or its subsidiaries collectively or Research Analysts or their relatives do not own 1% or more of the equity securities of the Company mentioned in the Research Report as of the last day of the month preceding the publication of the Research Report.

SMIFS encourages independence in Research Report preparation and strives to minimize conflict in preparation of Research Report. Accordingly, neither SMIFS and their Associates nor the Research Analysts and their relatives have any material conflict of interest at the time of publication of this Research Report or at the time of the Public Appearance, if any.

SMIFS or its associates might have managed or co-managed public offering of securities for the subject company or might have been mandated by the subject company for any other assignment in the past twelve months.

SMIFS or its associates might have received any compensation from the companies mentioned in the Research Report during the period preceding twelve months from the date of this Research Report for services in respect of managing or co-managing public offerings, corporate finance, investment banking, brokerage services or other advisory service in a merger or specific transaction from the subject company.

SMIFS or its associates might have received any compensation for products or services other than investment banking or brokerage services from the subject companies mentioned in the Research Report in the past twelve months.

SMIFS or its associates or its Research Analysts did not receive any compensation or other benefits whatsoever from the subject companies mentioned in the Research Report or third party in connection with preparation of the Research Report.

Compensation of Research Analysts is not based on any specific Investment Banking or Brokerage Service Transactions.

The Research Analysts might have served as an officer, director or employee of the subject company.

Neither the Research Analysts nor SMIFS have been engaged in market making activity for the companies mentioned in the Research Report.

SMIFS may have issued other Research Reports that are inconsistent with and reach different conclusion from the information presented in this Research Report.

A graph of daily closing prices of the securities/commodities is also available at [www.nseindia.com](http://www.nseindia.com) and/or [www.bseindia.com](http://www.bseindia.com), [www.mcxindia.com](http://www.mcxindia.com) and/or [www.icex.com](http://www.icex.com).

SMIFS submit' s that no material disciplinary action has been taken on the Company by any Regulatory Authority impacting Equity Research Analysis activities in last 3 years.

This Research Report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject SMIFS and affiliates to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction.

For queries related to compliance of the report, please contact: -

**Sudipto Datta, Compliance Officer**

**SMIFS Limited.**

**Vaibhav, 4 Lee Road, Kolkata 700020, West Bengal, India.**

**Contact No.: +91 33 4011 5414 /91 33 6634 5414**

**Email Id.: [compliance@smifs.com](mailto:compliance@smifs.com)**

**Website: [www.smifs.com](http://www.smifs.com)**